Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 1841 Neoplasms 1230 Colorectal Neoplasms 1046 Carcinoma, Non-Small-Cell Lung 996 Stomach Neoplasms 787 Carcinoma, Hepatocellular 780 Lung Neoplasms 756 Prostatic Neoplasms 682 Pancreatic Neoplasms 567 Rectal Neoplasms 444 Colonic Neoplasms 401 Neoplasm Metastasis 400 Ovarian Neoplasms 399 Uterine Cervical Neoplasms 395 Recurrence 380 Leukemia, Myeloid, Acute 367 Esophageal Neoplasms 352 Multiple Myeloma 340 Lymphoma 330 Head and Neck Neoplasms 326 Melanoma 306 Precursor Cell Lymphoblastic Leukemia-Lymphoma 288 Brain Neoplasms 263 Urinary Bladder Neoplasms 249 Nasopharyngeal Carcinoma 221 Liver Neoplasms 221 Leukemia 217 Lymphoma, Large B-Cell, Diffuse 213 Polycystic Ovary Syndrome 206 Squamous Cell Carcinoma of Head and Neck 200

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Feasibility × Clear all

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡